REGENXBIO INC (RGNX) Fundamental Analysis & Valuation

NASDAQ:RGNX • US75901B1070

Current stock price

7.76 USD
-0.5 (-6.05%)
At close:
7.65 USD
-0.11 (-1.42%)
After Hours:

This RGNX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. RGNX Profitability Analysis

1.1 Basic Checks

  • RGNX had negative earnings in the past year.
  • In the past year RGNX has reported a negative cash flow from operations.
  • In the past 5 years RGNX reported 4 times negative net income.
  • RGNX had negative operating cash flow in 4 of the past 5 years.
RGNX Yearly Net Income VS EBIT VS OCF VS FCFRGNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M -200M

1.2 Ratios

  • RGNX has a Return On Assets of -42.80%. This is comparable to the rest of the industry: RGNX outperforms 55.30% of its industry peers.
  • RGNX has a worse Return On Equity (-188.72%) than 68.21% of its industry peers.
Industry RankSector Rank
ROA -42.8%
ROE -188.72%
ROIC N/A
ROA(3y)-45.81%
ROA(5y)-31.92%
ROE(3y)-120.24%
ROE(5y)-79.66%
ROIC(3y)N/A
ROIC(5y)N/A
RGNX Yearly ROA, ROE, ROICRGNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

1.3 Margins

  • RGNX has a better Gross Margin (88.09%) than 89.60% of its industry peers.
  • RGNX's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for RGNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 88.09%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y19.48%
GM growth 5Y2.75%
RGNX Yearly Profit, Operating, Gross MarginsRGNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. RGNX Health Analysis

2.1 Basic Checks

  • RGNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, RGNX has more shares outstanding
  • RGNX has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for RGNX is higher compared to a year ago.
RGNX Yearly Shares OutstandingRGNX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
RGNX Yearly Total Debt VS Total AssetsRGNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • RGNX has an Altman-Z score of -3.16. This is a bad value and indicates that RGNX is not financially healthy and even has some risk of bankruptcy.
  • RGNX has a Altman-Z score (-3.16) which is comparable to the rest of the industry.
  • A Debt/Equity ratio of 1.43 is on the high side and indicates that RGNX has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 1.43, RGNX is doing worse than 77.84% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.43
Debt/FCF N/A
Altman-Z -3.16
ROIC/WACCN/A
WACC9.01%
RGNX Yearly LT Debt VS Equity VS FCFRGNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 2.38 indicates that RGNX has no problem at all paying its short term obligations.
  • RGNX's Current ratio of 2.38 is on the low side compared to the rest of the industry. RGNX is outperformed by 72.25% of its industry peers.
  • A Quick Ratio of 2.38 indicates that RGNX has no problem at all paying its short term obligations.
  • The Quick ratio of RGNX (2.38) is worse than 68.98% of its industry peers.
Industry RankSector Rank
Current Ratio 2.38
Quick Ratio 2.38
RGNX Yearly Current Assets VS Current LiabilitesRGNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. RGNX Growth Analysis

3.1 Past

  • RGNX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.54%, which is quite good.
  • The Revenue has grown by 104.54% in the past year. This is a very strong growth!
  • The Revenue has been growing slightly by 1.97% on average over the past years.
EPS 1Y (TTM)17.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.71%
Revenue 1Y (TTM)104.54%
Revenue growth 3Y14.78%
Revenue growth 5Y1.97%
Sales Q2Q%43%

3.2 Future

  • The Earnings Per Share is expected to grow by 24.96% on average over the next years. This is a very strong growth
  • RGNX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 37.29% yearly.
EPS Next Y28.82%
EPS Next 2Y20.68%
EPS Next 3Y16.9%
EPS Next 5Y24.96%
Revenue Next Year41.59%
Revenue Next 2Y32.13%
Revenue Next 3Y37.19%
Revenue Next 5Y37.29%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RGNX Yearly Revenue VS EstimatesRGNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
RGNX Yearly EPS VS EstimatesRGNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

0

4. RGNX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RGNX. In the last year negative earnings were reported.
  • Also next year RGNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RGNX Price Earnings VS Forward Price EarningsRGNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RGNX Per share dataRGNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

  • RGNX's earnings are expected to grow with 16.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.68%
EPS Next 3Y16.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RGNX Dividend Analysis

5.1 Amount

  • RGNX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RGNX Fundamentals: All Metrics, Ratios and Statistics

REGENXBIO INC

NASDAQ:RGNX (3/27/2026, 8:00:01 PM)

After market: 7.65 -0.11 (-1.42%)

7.76

-0.5 (-6.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-05
Earnings (Next)05-11
Inst Owners82.03%
Inst Owner Change-1.11%
Ins Owners7.71%
Ins Owner Change16.16%
Market Cap400.49M
Revenue(TTM)170.44M
Net Income(TTM)-193.88M
Analysts84.21
Price Target30.26 (289.95%)
Short Float %13.93%
Short Ratio6.23
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.71%
Min EPS beat(2)-33.31%
Max EPS beat(2)9.88%
EPS beat(4)1
Avg EPS beat(4)-30.51%
Min EPS beat(4)-75.63%
Max EPS beat(4)9.88%
EPS beat(8)3
Avg EPS beat(8)-11.74%
EPS beat(12)5
Avg EPS beat(12)-9.2%
EPS beat(16)5
Avg EPS beat(16)-10.76%
Revenue beat(2)1
Avg Revenue beat(2)1.09%
Min Revenue beat(2)-18.65%
Max Revenue beat(2)20.83%
Revenue beat(4)1
Avg Revenue beat(4)-9.44%
Min Revenue beat(4)-25.51%
Max Revenue beat(4)20.83%
Revenue beat(8)2
Avg Revenue beat(8)-11.17%
Revenue beat(12)3
Avg Revenue beat(12)-16.57%
Revenue beat(16)4
Avg Revenue beat(16)-14.93%
PT rev (1m)-1.62%
PT rev (3m)-7.74%
EPS NQ rev (1m)-167.36%
EPS NQ rev (3m)-324.45%
EPS NY rev (1m)-4.75%
EPS NY rev (3m)8.92%
Revenue NQ rev (1m)-72.12%
Revenue NQ rev (3m)-66.84%
Revenue NY rev (1m)-5.51%
Revenue NY rev (3m)-9.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.35
P/FCF N/A
P/OCF N/A
P/B 3.9
P/tB 3.9
EV/EBITDA N/A
EPS(TTM)-3.76
EYN/A
EPS(NY)-2.68
Fwd EYN/A
FCF(TTM)-2.45
FCFYN/A
OCF(TTM)-2.4
OCFYN/A
SpS3.3
BVpS1.99
TBVpS1.99
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.8%
ROE -188.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 88.09%
FCFM N/A
ROA(3y)-45.81%
ROA(5y)-31.92%
ROE(3y)-120.24%
ROE(5y)-79.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y19.48%
GM growth 5Y2.75%
F-Score4
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity 1.43
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.46%
Cap/Sales 1.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.38
Quick Ratio 2.38
Altman-Z -3.16
F-Score4
WACC9.01%
ROIC/WACCN/A
Cap/Depr(3y)29.33%
Cap/Depr(5y)240.61%
Cap/Sales(3y)5.13%
Cap/Sales(5y)12.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.71%
EPS Next Y28.82%
EPS Next 2Y20.68%
EPS Next 3Y16.9%
EPS Next 5Y24.96%
Revenue 1Y (TTM)104.54%
Revenue growth 3Y14.78%
Revenue growth 5Y1.97%
Sales Q2Q%43%
Revenue Next Year41.59%
Revenue Next 2Y32.13%
Revenue Next 3Y37.19%
Revenue Next 5Y37.29%
EBIT growth 1Y30.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.11%
EBIT Next 3Y21.54%
EBIT Next 5Y28.18%
FCF growth 1Y28.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28.4%
OCF growth 3YN/A
OCF growth 5YN/A

REGENXBIO INC / RGNX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of REGENXBIO INC (RGNX) stock?

ChartMill assigns a fundamental rating of 2 / 10 to RGNX.


What is the valuation status for RGNX stock?

ChartMill assigns a valuation rating of 0 / 10 to REGENXBIO INC (RGNX). This can be considered as Overvalued.


Can you provide the profitability details for REGENXBIO INC?

REGENXBIO INC (RGNX) has a profitability rating of 2 / 10.


What is the financial health of REGENXBIO INC (RGNX) stock?

The financial health rating of REGENXBIO INC (RGNX) is 2 / 10.